Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2002 August;93(4) > Minerva Medica 2002 August;93(4):315-22

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236


eTOC

 

THERAPEUTICAL NOTES  


Minerva Medica 2002 August;93(4):315-22

language: Italian

Long term study on the efficacy and safety of lornoxicam in rheumatoid arthritis

Frizziero L., Focherini M. C., Valentini M., Reta M., Rocchi P.


PDF  


Background. To assess the long term safety and therapeutic action of lornoxicam, a new non steroidal anti-inflammatory agent, in rheumatoid arthritis.
Methods. Open trial was carried out on different dosage schedules of lornoxicam (4 or 8 mg bid and 4mg tid) administered for six to twelve months. Patients of both sexes were enrolled, with classical or definite rheumatoid arthritis according to the A.R.A. criteria.
Results. Thirty-four patients (28 F, 6 M) were admitted, mean age (± SD) 53.9±14.2 years, mean duration of illness 9.2±10.7 years. Lornoxicam 8-16 mg/day showed good safety and therapeutic activity in long term treatment. Clinical improvement was limited, but progression of the disease was controlled. No adverse events were complained.
Conclusions. Lornoxicam presented a worth-while therapeutic action and a good tolerability in rheumatoid arthritis long term treatment.

top of page

Publication History

Cite this article as

Corresponding author e-mail